Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study
Background Atopic dermatitis (AD) is characterized by flares of eczematous lesions accompanied by intense pruritus, which can tremendously impact quality of life (QoL). Despite continuous therapeutic progress, there are still unmet needs regarding AD management.Objective This sub-analysis of the cro...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2415407 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115105761525760 |
|---|---|
| author | Basile Darbellay Melanie Huber Izak Johannes Bisschoff Caroline Guillod Rainer Hügel Detlev Pirkhammer Paul G. Sator Timur Taskesen Claudia C. V. Lang |
| author_facet | Basile Darbellay Melanie Huber Izak Johannes Bisschoff Caroline Guillod Rainer Hügel Detlev Pirkhammer Paul G. Sator Timur Taskesen Claudia C. V. Lang |
| author_sort | Basile Darbellay |
| collection | DOAJ |
| description | Background Atopic dermatitis (AD) is characterized by flares of eczematous lesions accompanied by intense pruritus, which can tremendously impact quality of life (QoL). Despite continuous therapeutic progress, there are still unmet needs regarding AD management.Objective This sub-analysis of the cross-sectional global study MEASURE-AD with 1558 AD patients treated with or eligible for systemic therapy aimed at characterizing the real-world burden of 98 patients in Austria and Switzerland. Patients were enrolled between October 2019 and June 2020. Assessing patient characteristics, treatment, disease severity, and patient-reported outcomes.Results Mean age at time of diagnosis was 19.4 years with delayed diagnosis by an average of almost 3 years. All patients obtained treatment, 57.1% of them systemic therapy, mostly dupilumab. 45.9%–73.5% of all patients presented with moderate to severe disease and more than half of them suffered from moderate to severe pruritus, impaired QoL, and had experienced several flares. Furthermore, a negative impact on sleep, mental health, social life, and work productivity was revealed.Conclusions This analysis confirms that AD is associated with a multidimensional burden despite treatment and demonstrates unmet needs regarding diagnostic delay, under-treatment with systemic therapy, and the development of efficacious therapies to improve clinical symptoms and QoL. |
| format | Article |
| id | doaj-art-12629af1940c4e40a031895f0c0678f7 |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-12629af1940c4e40a031895f0c0678f72025-08-20T02:36:40ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2415407Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD studyBasile Darbellay0Melanie Huber1Izak Johannes Bisschoff2Caroline Guillod3Rainer Hügel4Detlev Pirkhammer5Paul G. Sator6Timur Taskesen7Claudia C. V. Lang8Institut central des hopitaux valaisans (ICHV), Sion, SwitzerlandUFL Private University in the Principality of Liechtenstein, Triesen, LiechtensteinMedizin am Hauptbahnhof, Vienna, AustriaDepartment of Dermatology, Bellinzona Regional Hospital, Bellinzona, SwitzerlandSkin Inflammation Centre, Vienna, AustriaDepartment of Dermatology, Klinik Landstrasse, Vienna, AustriaDermatology, Institute for clinical research on skin diseases of the Karl Landsteiner society, Vienna, AustriaDermaesthetik Hautärzte, Zurich, SwitzerlandDepartment of Dermatology, University Hospital Zurich, Zurich, SwitzerlandBackground Atopic dermatitis (AD) is characterized by flares of eczematous lesions accompanied by intense pruritus, which can tremendously impact quality of life (QoL). Despite continuous therapeutic progress, there are still unmet needs regarding AD management.Objective This sub-analysis of the cross-sectional global study MEASURE-AD with 1558 AD patients treated with or eligible for systemic therapy aimed at characterizing the real-world burden of 98 patients in Austria and Switzerland. Patients were enrolled between October 2019 and June 2020. Assessing patient characteristics, treatment, disease severity, and patient-reported outcomes.Results Mean age at time of diagnosis was 19.4 years with delayed diagnosis by an average of almost 3 years. All patients obtained treatment, 57.1% of them systemic therapy, mostly dupilumab. 45.9%–73.5% of all patients presented with moderate to severe disease and more than half of them suffered from moderate to severe pruritus, impaired QoL, and had experienced several flares. Furthermore, a negative impact on sleep, mental health, social life, and work productivity was revealed.Conclusions This analysis confirms that AD is associated with a multidimensional burden despite treatment and demonstrates unmet needs regarding diagnostic delay, under-treatment with systemic therapy, and the development of efficacious therapies to improve clinical symptoms and QoL.https://www.tandfonline.com/doi/10.1080/09546634.2024.2415407Atopic dermatitisburden of diseasereal-worldMEASURE AD study |
| spellingShingle | Basile Darbellay Melanie Huber Izak Johannes Bisschoff Caroline Guillod Rainer Hügel Detlev Pirkhammer Paul G. Sator Timur Taskesen Claudia C. V. Lang Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study Journal of Dermatological Treatment Atopic dermatitis burden of disease real-world MEASURE AD study |
| title | Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study |
| title_full | Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study |
| title_fullStr | Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study |
| title_full_unstemmed | Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study |
| title_short | Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study |
| title_sort | real world burden of atopic dermatitis austrian and swiss data from the measure ad study |
| topic | Atopic dermatitis burden of disease real-world MEASURE AD study |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2415407 |
| work_keys_str_mv | AT basiledarbellay realworldburdenofatopicdermatitisaustrianandswissdatafromthemeasureadstudy AT melaniehuber realworldburdenofatopicdermatitisaustrianandswissdatafromthemeasureadstudy AT izakjohannesbisschoff realworldburdenofatopicdermatitisaustrianandswissdatafromthemeasureadstudy AT carolineguillod realworldburdenofatopicdermatitisaustrianandswissdatafromthemeasureadstudy AT rainerhugel realworldburdenofatopicdermatitisaustrianandswissdatafromthemeasureadstudy AT detlevpirkhammer realworldburdenofatopicdermatitisaustrianandswissdatafromthemeasureadstudy AT paulgsator realworldburdenofatopicdermatitisaustrianandswissdatafromthemeasureadstudy AT timurtaskesen realworldburdenofatopicdermatitisaustrianandswissdatafromthemeasureadstudy AT claudiacvlang realworldburdenofatopicdermatitisaustrianandswissdatafromthemeasureadstudy |